The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a pr
The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a preparation of hydrophilic cellular components and a preparation of hydrophobic cellular components. In some embodiments, the preparation of hydrophilic cellular components is encapsulated within the internal lumen and the preparation of hydrophobic cellular components is associated with the external surface. Various methods of making and using disclosed nanoparticle compositions are also provided.
대표청구항▼
1. A pharmaceutical composition comprising: (a) a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure whose external surface-is coated with (i) a preparation comprising a crude hydrophobic bacterial extract; and(ii)
1. A pharmaceutical composition comprising: (a) a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure whose external surface-is coated with (i) a preparation comprising a crude hydrophobic bacterial extract; and(ii) a hydrophilic antigen encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to a subject, the antigen is hidden from immune system components; and(b) at least one pharmaceutically acceptable excipient. 2. The pharmaceutical composition of claim 1, wherein the composition is formulated for intravenous, intradermal, transdermal, oral, subcutaneous, and/or transmucosal administration. 3. The pharmaceutical composition of claim 1, wherein the nanoparticles each further comprise a preparation comprising one or more hydrophilic cellular components. 4. The pharmaceutical composition of claim 1, wherein the nanoparticles each further comprise a second antigen, optionally also encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to a subject, the antigen is hidden from immune system components. 5. The pharmaceutical composition of claim 1, wherein the antigen is selected from the group consisting of an allergic antigen, an anaphylactic antigen, an infectious antigen, an autoantigen, a disease-associated antigen, a food antigen, a microbial antigen, a viral antigen, a tumor antigen, and an environmental antigen. 6. The pharmaceutical composition of claim 1, wherein the biodegradable or biocompatible polymer is poly(lactic-co-glycolic acid). 7. A method comprising: treating a human subject suffering from or susceptible to at least two distinct allergic conditions by administering to a human subject in need thereof at least one nanoparticle composition comprising a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure whose external surface is coated with a preparation comprising a crude hydrophobic bacterial extract; anda hydrophilic antigen encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to the human subject, the antigen is hidden from the subject's immune system components. 8. The method of claim 7, wherein the administration comprises at least two nanoparticle compositions, wherein each of the two nanoparticle compositions comprises a distinct antigen. 9. A nanoparticle composition comprising: a plurality of nanoparticles, each of which is comprised of:(a) poly(lactic-co-glycolic acid) arranged in a nanoparticle structure whose external surface-is coated with a preparation comprising a crude hydrophobic bacterial extract; and(b) a hydrophilic antigen, which antigen is selected from the group consisting of: an allergic antigen, an anaphylactic antigen, an infectious antigen, an autoantigen, a disease-associated antigen, a food antigen, a microbial antigen, a viral antigen, a tumor antigen, and an environmental antigen, and(c) one or more hydrophilic cellular components, wherein the hydrophilic antigen and cellular components are encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to a subject, the antigen is hidden from immune system components.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (107)
Eberle Marcel K. (Riehen CHX), 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8cyclosporins.
Sinclair Peter J. (Highland Park NJ) Organ Helen M. (Roselle Park NJ) Wyvratt Matthew J. (Mountainside NJ), Amino O-aryl macrolides having immunosuppressive activity.
Ok Hyun O. (Edison NJ) Beattie Thomas R. (Scotch Plains NJ) Fisher Michael H. (Ringoes NJ) Wyvratt Matthew J. (Mountainside NJ) Goulet Mark (Westfield NJ), Aminomacrolides and derivatives having immunosuppressive activity.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Molnar-Kimber Katherine L. (Glenside PA) Ocain Timothy D. (Waltham MA) Vernon Steven K. (Havertown PA) Huang John J. (San Carlos CA), Biotin esters of rapamycin.
Goulet Mark (Westfield NJ) Beattie Thomas R. (Scotch Plains NJ) Wyvratt Matthew J. (Mountainside NJ), Fluoromacrolides having immunosuppressive activity.
Patchett Arthur A. (Westfield NJ) Taub David (Metuchen NJ) Goegelman Robert T. (Linden NJ), Immunosuppressive cyclosporin analogs with modified amino acids at position-8.
Durette Philippe L. (New Providence NJ) Pessolano Arsenio A. (Colonia NJ) Kollonitsch Janos (Westfield NJ), Immunosuppressive fluorinated cyclosporin analogs.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Ok Hyun O. (Edison NJ) Goulet Joung (Westfield NJ) Sinclair Peter J. (Highland Park NJ), N-heteroaryl, N-alkylheteroaryl, N-alkenylheteroaryl and N-alkynylheteroarylmacrolides having immunosuppressive activity.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Burks, Jr.,A. Wesley; Bannon,Gary A.; Sampson,Hugh A.; Helm,Ricki M.; Stanley,J. Steven; Rabjohn,Patrick A., Nucleic acids encoding ara h 3 polypeptides.
Goulet Mark (Westfield NJ) Organ Helen M. (Fanwood NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity.
Goulet Mark (Westfield NJ) Wong Frederick (Glen Ridge NJ) Sinclair Peter J. (Highland Park NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Organ Helen M. (Fanwood NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity.
A. Wesley Burks, Jr. ; J. Steven Stanley ; Gael Cockrell ; Nina E. King ; Hugh A. Sampson ; Ricki M. Helm ; Gary A. Bannon, Peanut allergens and methods.
Okuhara Masakuni (Ibaraki JPX) Tanaka Hirokazu (Ibaraki JPX) Goto Toshio (Ibaraki JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Ibaraki JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
Okuhara Masakuni (Ibaraki JPX) Tanaka Hirokazu (Ibaraki JPX) Goto Toshio (Ibaraki JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Ibaraki JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
Okuhara Masakuni (Sakuramura JPX) Tanaka Hirokazu (Sakuramura JPX) Goto Toshio (Sakuramura JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Sakuramura JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.